<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>Operator_BCSC1819_S12_C06_p121-148_pass_2p</title>
		<link href="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="Operator_BCSC1819_S12_C06_p121-148_pass_2p" lang="en-US">
		<div id="_idContainer007" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">CHAPTER</span><span class="cn-chap"> </span>6</p>
			<p class="chapter-title">Retinal Vascular Diseases Associated With Cardiovascular Disease</p>
			<p class="activity-intro ParaOverride-1"><img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" />&#9;<span class="italic">This chapter includes related activities, which can be accessed by scanning the QR codes provided in the text or going to </span><a href="http://www.aao.org/bcscactivity_section12">www.aao.org/bcscactivity_section12</a><span class="italic">.</span></p>
			<p class="body-text--no-indent-">This chapter discusses ret&#173;i&#173;nal vascular diseases that are associated in some way with cardiovascular disease. When evaluating patients, it is impor&#173;tant to consider the additional risk &#173;factors linked to many of &#173;these conditions.</p>
			<p class="h1 ParaOverride-2">Systemic Arterial Hypertension</p>
			<div id="Chapt6_Top1">
			<p class="body-text--no-indent-">Systemic arterial hypertension affects more than 72 million &#173;people in the United States. Hypertension is currently divided into 3 stages: elevated encompasses blood pressure readings of 120–129&#160;mm Hg systolic or &lt;80&#160;mm Hg diastolic; stage 1 hypertension includes readings of 130–139&#160;mm Hg systolic or 80–89&#160;mm Hg diastolic pressure; and stage 2 hypertension refers to readings of 140&#160;mm Hg or higher systolic and 90&#160;mm Hg or higher diastolic pressure.</p>
			<p class="body-text">Together with heart, kidneys, and brain, the eye is a major target organ of systemic hypertension. Ocular effects of hypertension can be observed in the ret&#173;ina, choroid, and optic nerve. Ret&#173;i&#173;nal changes can be described and classified using ophthalmoscopy and angiography. An ophthalmologist’s recognition of posterior segment vascular changes may even prompt the initial diagnosis of hypertension and alert the patient to the potential complications associated with this condition. BCSC Section&#160;1, <span class="italic">Update on General Medicine,</span> discusses hypertension in more detail.</p>
			<p class="reference--non-journal--single ParaOverride-3">Kim SK, Mieler WF, Jakobiec&#160;F. Hypertension and its ocular manifestations. In: Albert DM, Miller JW, Azar DT, Blodi BA, eds. <span class="italic">Albert &amp; Jakobiec’s Princi&#173;ples and Practice of Ophthalmology.</span> 3rd&#160;ed. Philadelphia: Saunders; 2008:4367–4384.</p>
			<p class="h2 ParaOverride-4">Hypertensive Retinopathy</p>
			<p class="body-text--no-indent-">Hypertension affects arterioles and capillaries, the anatomic loci of both autoregulation and nonperfusion. An acute hypertensive episode may produce focal intraret&#173;i&#173;nal periarteriolar transudates (FIPTs) at the precapillary level. The presence of cotton-&#173;wool spots (also referred to as <span class="italic">soft exudates</span>) indicates ischemia of the ret&#173;i&#173;nal nerve fiber layer (<span class="xref-figure">Fig 6-1</span>). Uncontrolled systemic hypertension leads to nonperfusion at vari&#173;ous ret&#173;i&#173;nal levels as well as neuronal loss and associated scotomas. Other, more chronic, hypertensive ret&#173;i&#173;nal lesions include microaneurysms, intraret&#173;i&#173;nal microvascular abnormalities (IRMAs), blot hemorrhages, lipid exudates (also referred to as <span class="italic">hard exudates</span> <span class="italic">or</span> <span class="italic">edema </span><span class="italic">residues</span>), venous beading, and neovascularization. The relationship between hypertensive vascular changes and arteriosclerotic vascular disease is complex, with wide variation related to the duration and severity of the hypertension, the presence of diabetic retinopathy, the severity of any dyslipidemia, patient age, and the patient’s history of smoking. Hence, it is difficult to classify which ret&#173;i&#173;nal vascular changes have been caused strictly by hypertension; the often-&#173;cited focal arteriolar narrowing and arterial venous nicking have been shown to have &#173;little predictive value for &#173;actual hypertension severity. Nonetheless, one historical classification of mostly arteriosclerotic retinopathy is the Modified Scheie Classification of Hypertensive Retinopathy:</p>
			<p class="unnumbered-list-first ParaOverride-5">Grade 0 No changes</p>
			<p class="unnumbered-list-mid">Grade 1 Barely detectable arterial narrowing</p>
			<p class="unnumbered-list-mid">Grade 2 Obvious arterial narrowing with focal irregularities</p>
			<p class="unnumbered-list-mid">Grade 3 Grade 2 plus ret&#173;i&#173;nal hemorrhages and/or exudates</p>
			<p class="unnumbered-list-last ParaOverride-6">Grade 4 Grade 3 plus optic nerve head swelling</p>
			<p class="body-text">Hypertension may be complicated by branch ret&#173;i&#173;nal artery occlusion (BRAO), branch ret&#173;i&#173;nal vein occlusion (BRVO), central ret&#173;i&#173;nal vein occlusion (CRVO), or ret&#173;i&#173;nal arterial macroaneurysms (all discussed &#173;later in this chapter). In addition, the coexistence of hypertension and diabetes mellitus results in more severe retinopathy &#173;because precapillary and capillary insults act in combination.</p>
			<p class="reference--non-journal--first">Cheung CYL, Wong TY. Hypertension. In: Schachat AP, Wilkinson CP, Hinton DR, Sadda SR, Wiedemann P, eds. <span class="italic">Ryan’s</span> <span class="italic">Ret&#173;i&#173;na.</span> 6th&#160;ed. Philadelphia: Elsevier/Saunders; 2018:<br />chap 52.</p>
			<p class="reference--journal--last ParaOverride-7">Wong TY, Mitchell&#160;P. The eye in hypertension. <span class="italic">Lancet.</span> 2007;369(9559):425–435.</p>
			<p class="h2 ParaOverride-8">Hypertensive Choroidopathy</p>
			<p class="body-text--no-indent-">Hypertensive choroidopathy typically occurs in young patients who have experienced an episode of acute, severe hypertension often associated with preeclampsia, eclampsia, pheochromocytoma, or renal hypertension (see <span class="xref-local">Chapter&#160;9 for more on choroidal disease</span>). Lobular nonperfusion of the choriocapillaris may occur, initially resulting in tan, lobule-&#173;sized patches that, in time, become hyperpigmented and surrounded by margins of hypopigmentation—&#173;lesions known as <span class="italic">Elschnig spots</span> (<span class="xref-figure">Fig 6-2</span>). Linear configurations&#160;of similar-&#173;appearing hyperpigmentations known as <span class="italic">Siegrist streaks</span> follow the meridional course of choroidal arteries. Fluorescein angiography shows focal choroidal hypoperfusion in the early phases and multiple subret&#173;i&#173;nal areas of leakage in the late phases (<span class="xref-figure">Fig </span><span class="xref-figure">6-3</span>). Focal ret&#173;i&#173;nal pigment epithelium (RPE) detachments may occur, and, in severe cases, extensive bilateral exudative ret&#173;i&#173;nal detachments may develop.</p>
			<p class="h2 ParaOverride-8">Hypertensive Optic Neuropathy</p>
			<p class="body-text--no-indent-">Patients with optic neuropathy secondary to severe hypertension may exhibit linear peripapillary flame-&#173;shaped hemorrhages, blurring of the optic nerve head margins, florid optic nerve head edema with secondary ret&#173;i&#173;nal venous stasis, and macular exudates (<span class="xref-figure">Fig&#160;6-4</span>). The differential diagnosis for patients with this clinical appearance includes CRVO, anterior ischemic optic neuropathy, diabetic papillopathy, radiation papillopathy, and neuroretinitis.</p>
			</div>
			<p class="h1 ParaOverride-2">Retinal Vein Occlusion</p>
			<div id="Chapt6_Top2">
			<p class="body-text--no-indent-">Ret&#173;i&#173;nal vein occlusion (RVO) is most commonly associated with advancing age and hypertension; however, it also has less common or rare associations. A patient with RVO should be medically evaluated, and, in the absence of cardiovascular disease, a search for other causative or predisposing systemic conditions should be considered, especially among patients younger than 50&#160;years old.</p>
			<p class="body-text">All patients with RVO should undergo a comprehensive ocular examination. Glaucoma, in both open-&#173; and narrow-&#173;angle forms, is a major risk &#173;factor for RVO. In the Eye Disease Case-&#173;Control Study (EDCC), a history of glaucoma was found to increase a patient’s risk of CRVO by a &#173;factor of 5.3, and of BRVO by a &#173;factor of 2.5. Elevated ret&#173;i&#173;nal venous pressure and reduced blood flow are thought to be among the few avoidable &#173;factors associated with both branch and central ret&#173;i&#173;nal vein occlusion. Ret&#173;i&#173;nal venous pressure may increase in the supine position (ie, when sleeping), and blood pressure medi&#173;cations can reduce perfusion pressure and blood flow; therefore, it has been suggested that patients should avoid taking their blood pressure medi&#173;cations at bedtime.</p>
			<p class="body-text">Intraret&#173;i&#173;nal hemorrhages and dilated tortuous ret&#173;i&#173;nal vasculature are classic findings in the affected ret&#173;ina, and in severe cases, cotton-&#173;wool spots may be pres&#173;ent (<span class="xref-figure">Fig 6-5</span>). In acute disease, the level of visual acuity impairment depends on the severity of the macular ischemia or edema and the presence of intraret&#173;i&#173;nal hemorrhages affecting the fovea. Macular edema is best assessed with spectral-&#173;domain optical coherence tomography (SD-&#173;OCT), while ischemia is best detected using fluorescein angiography or OCT angiography. Without treatment, increasing amounts of ischemic ret&#173;ina confer increasing risk for neovascularization. In patients with BRVO, neovascularization most commonly occurs in the healthy ret&#173;ina at the border of the affected, ischemic ret&#173;ina or, less commonly, at the optic nerve head, and, in rare instances, in the anterior segment. In patients with CRVO, neovascularization occurs most commonly in the anterior segment, manifesting as iris or &#173;angle neovascularization, but can also occur in in the ret&#173;ina or at the optic nerve head. &#173;Because anterior segment neovascularization is found in both branch and central ret&#173;i&#173;nal vein occlusions, periodic, undilated examinations of the iris and gonioscopic &#173;angle is recommended for all patients with RVO.</p>
			<p class="body-text">Improvement or spontaneous resolution can occur in patients with RVO. Improvement is usually associated with the development of adequate collateral blood flow. In BRVO, capillaries extending across the median raphe dilate, helping to compensate for the compromised venous drainage. In CRVO, small vessels that normally connect the ret&#173;i&#173;nal circulation to the choroidal circulation near the optic nerve head expand, resulting in the undulating appearance of optociliary shunt vessels. &#173;These mechanisms redirect venous drainage to the choroid, vortex veins, and superior and inferior ophthalmic veins in the orbit, bypassing the occluded central ret&#173;i&#173;nal vein. Chronic, untreated venous occlusive disease commonly leads to development of ret&#173;i&#173;nal microvascular changes characterized by microaneurysms, telangiectasias, and macular edema (<span class="xref-figure">Fig 6-6</span>).</p>
			<p class="body-text">Anti–&#173;vascular endothelial growth &#173;factor (VEGF) drugs are mainstay of RVO treatment &#173;because of their excellent efficacy and safety profiles. Best visual acuity outcomes are achieved by administering anti-&#173;VEGF treatment immediately upon diagnosis of RVO-&#173;related macular edema. Anti-&#173;VEGF treatment also suppresses neovascular complications of RVO. Intraocular ste&#173;roid treatments and macular or scatter panret&#173;i&#173;nal photocoagulation are also employed to manage vision loss from, and complications of,&#160;RVO.</p>
			<p class="body-text">Specific considerations for branch and central ret&#173;i&#173;nal vein occlusion are discussed in the following sections.</p>
			<p class="reference--non-journal--first ParaOverride-9">Goldman DR, Shah CP, Morley MG, Heier JS. Venous occlusive disease of the ret&#173;ina. In: Yanoff M, Duker JS, eds. <span class="italic">Ophthalmology.</span> 4th&#160;ed. Philadelphia: Elsevier/Saunders; 2014: 526–534.</p>
			<p class="reference--non-journal--last ParaOverride-7">Hayreh SS. Ret&#173;i&#173;nal vein occlusion. <span class="italic">Indian J Ophthalmol.</span> 1994;42(3):109–132.</p>
			<p class="h2 ParaOverride-4">Branch Ret&#173;i&#173;nal Vein Occlusion</p>
			<p class="body-text--no-indent-">In BRVO, obstruction of the vein occurs most commonly at an arteriovenous crossing, where thickening of the arterial wall compresses the adjacent vein within a common adventitial sheath. When the occlusion does not occur at an arteriovenous crossing, the possibility of an under&#173;lying retinochoroiditis or ret&#173;i&#173;nal vasculitis should be considered. The quadrant most commonly affected is the superotemporal (63%); a clinical finding of nasal vascular occlusion is rare. The artery serving the area of venous occlusion may become narrowed and sheathed over time.</p>
			<p class="h3 ParaOverride-4">Risk &#173;factors for the development of BRVO</p>
			<p class="body-text--no-indent-">The mean age of patients at the time of occurrence is in the seventh de&#173;cade. The EDCC and other studies have identified the following risk &#173;factors for the development of BRVO:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-10">increasing age</li>
				<li class="bullet-list-mid">history of systemic arterial hypertension</li>
				<li class="bullet-list-mid">history of smoking</li>
				<li class="bullet-list-mid">history of glaucoma</li>
				<li class="bullet-list-last">hypercoagulable conditions</li>
			</ul>
			<p class="body-text--no-indent-">Other studies have disputed the role of smoking or glaucoma as risk &#173;factors for BRVO. Diabetes mellitus was not a major in&#173;de&#173;pen&#173;dent risk &#173;factor in the EDCC, although 10%–12% of patients with RVO have the disease.</p>
			<p class="h3 ParaOverride-4">Prognosis for patients with BRVO</p>
			<p class="body-text--no-indent-">In acute disease, the presence or absence of macular or foveal involvement determines the visual prognosis. Prior to the availability of pharmacologic intervention, the Branch Vein Occlusion Study (BVOS) found that the incidence of neovascularization from the ret&#173;ina or optic nerve was 36% in eyes with extensive ret&#173;i&#173;nal ischemia; extensive ischemia was defined as an area of at least 5 disc dia&#173;meters in size. Vitreous hemorrhage developed in 60%–90% of such eyes if &#173;laser photocoagulation was not performed.</p>
			<p class="body-text">Over the long term, permanent vision loss may be related to macular ischemia, cystoid macular edema (CME), lipid residues (hard exudates) in the fovea, pigmentary macular disturbances, subret&#173;i&#173;nal fibrosis, and epiret&#173;i&#173;nal membrane formation. Less common &#173;causes of vision loss include vitreous hemorrhage, tractional ret&#173;i&#173;nal detachment, and rhegmatogenous ret&#173;i&#173;nal detachment (RRD). RRD typically develops following a break in ret&#173;ina adjacent to, or under&#173;lying ret&#173;i&#173;nal neovascularization induced by vitreous traction.</p>
			<p class="h3 ParaOverride-4">Treatment of BRVO</p>
			<p class="h4-text ParaOverride-11"><span class="h4-head">Pharmacologic management</span> Pharmacologic management is currently the mainstay of RVO management. See the section Pharmacologic Management of Ret&#173;i&#173;nal Vein Occlusion for a discussion of this topic.</p>
			<p class="h4-text ParaOverride-12"><span class="h4-head">Surgical management of BRVO</span></p>
			<p class="h5-text ParaOverride-11"><span class="h5-head">macular &#173;laser surgery</span> &#173;Laser grid photocoagulation may be applied to areas of macular edema caused by the obstructed vein (<span class="xref-figure">Fig 6-7</span>). The BVOS found that laser-&#173;treated eyes with intact foveal vasculature, macular edema, and visual acuity in the 20/40–20/200 range &#173;were more likely to gain 2 lines of visual acuity (65%) than untreated eyes (37%). At 3-&#173;year follow-up, treated eyes &#173;were more likely to have 20/40 or better visual acuity than untreated eyes (60% vs 34%, respectively), with a mean visual acuity improvement of 1.3&#160;ETDRS (Early Treatment of Diabetic Retinopathy Study) lines versus 0.2 line, respectively. In the BVOS, &#173;laser treatment of macular edema was delayed for at least 3 months to permit the maximum spontaneous resolution of intraret&#173;i&#173;nal blood and the edema. While this practice may still be appropriate for macular &#173;laser therapy, treatment with pharmacologic agents should commence immediately upon diagnosis of BRVO.</p>
			<p class="h5-text"><span class="h5-head">scatter photocoagulation</span> The BVOS showed that scatter photocoagulation to the area of ret&#173;i&#173;nal capillary nonperfusion is effective in causing regression of the new vessels in eyes with ret&#173;i&#173;nal, optic nerve head, or iris neovascularization (<span class="xref-figure">Fig 6-8</span>); it also reduced the risk of vitreous hemorrhage from 60% to 30%. Although the BVOS showed that patients with large areas of nonperfusion (see Fig&#160;6-5) &#173;were found to be at significant risk of developing neovascularization, the study concluded that ischemia alone was not an indication for treatment, provided that follow-up could be maintained.</p>
			<p class="body-text">Clinically, it is impor&#173;tant to distinguish neovascularization of the optic nerve head or ret&#173;ina from collateral vessels, which have a larger caliber and do not leak when viewed with fluorescein angiography. Neovascularization of the iris occurs in approximately 2% of eyes with BRVO. In &#173;these cases, scatter &#173;laser photocoagulation in the distribution of the occluded vein should be considered to prevent the development of neovascular glaucoma.</p>
			<p class="reference--non-journal--single">Fuller JJ, Mason JO III. Ret&#173;i&#173;nal vein occlusions: update on diagnostic and therapeutic advances. <span class="italic">Focal Points: Clinical Modules for Ophthalmologists.</span> San Francisco: American Acad&#173;emy of Ophthalmology; 2007, module 5.</p>
			<p class="h5-text"><span class="h5-head">pars plana vitrectomy</span> Vitrectomy may be indicated for eyes that develop vitreous hemorrhage or ret&#173;i&#173;nal detachment (also see <span class="xref-local">Chapters&#160;16</span> and <span class="xref-local">20&#160;in this volume</span>).</p>
			<p class="h2">Central Ret&#173;i&#173;nal Vein Occlusion</p>
			<p class="body-text--no-indent-">In CRVO, vision loss is most commonly sudden, with severity ranging along a continuum from mild (nonischemic) to severe (ischemic). Less commonly, patients may experience premonitory symptoms of transient obscuration of vision before overt ret&#173;i&#173;nal manifestations appear. CRVOs are considered intermediate, or indeterminate, if they are neither clearly ischemic nor nonischemic; however, more than 80% of intermediate eyes progressed to ischemic disease in the Central Vein Occlusion Study (CVOS).</p>
			<p class="body-text">Nonischemic (mild) CRVO, sometimes referred to as <span class="italic">partial, perfused,</span> or <span class="italic">venous stasis retinopathy,</span> is characterized by visual acuity of 20/200 or better, mild or no afferent pupillary defect, and mild visual field changes. Ophthalmoscopy shows mild dilation and tortuosity of all branches of the central ret&#173;i&#173;nal vein as well as dot-&#173; and flame-&#173;shaped hemorrhages in all quadrants of the ret&#173;ina (<span class="xref-figure">Fig 6-9</span>). Macular edema with decreased visual acuity and mild optic nerve head swelling may be pres&#173;ent (<span class="xref-figure">Activity 6-1; Fig 6-10</span>). Fluorescein angiography usually demonstrates prolongation of the ret&#173;i&#173;nal circulation time with breakdown of capillary permeability but minimal areas of nonperfusion. Anterior segment neovascularization is rare in mild CRVO. Chronic nonischemic changes from CRVO include telangiectasias, microaneurysms, and macular pigmentary changes (see Fig 6-6).</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer001" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="activity-first-verso ParaOverride-13"><span class="QR-code-activity-number">ACTIVITY 6-1</span> OCT Activity: Macular OCT of CRVO eye with severe CME <br />and foveal detachment.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer003" class="_idGenObjectStyleOverride-1">
					<div id="_idContainer002" class="_idGenObjectStyleOverride-1">
						<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
					</div>
				</div>
			</div>
			<p class="activity-source-verso ParaOverride-14">Courtesy of Colin&#160;A. McCannel, MD.</p>
			<p class="activity-last-verso ParaOverride-13">Access all Section 12 activities at <a href="http://www.aao.org/bcscactivity_section12">www.aao.org/bcscactivity_section12</a>.</p>
			<p class="body-text">Ischemic (severe) CRVO, also known as <span class="italic">complete, nonperfused,</span> or <span class="italic">hemorrhagic retinopathy,</span> is defined as having at least 10 optic disc areas of ret&#173;i&#173;nal capillary nonperfusion on fluorescein angiography. Ischemic cases are usually associated with poor vision, an afferent pupillary defect, dense central scotoma, and peripheral field constriction. Marked venous dilation, more extensive 4-&#173;quadrant hemorrhage, ret&#173;i&#173;nal edema (<span class="xref-figure">Fig 6-11</span>), and variable numbers of cotton-&#173;wool spots are frequently found as well. Fluorescein angiography circulation times are typically prolonged and widespread capillary nonperfusion is demonstrated. &#173;Because of inner ret&#173;i&#173;nal dysfunction due to ischemia, the b-&#173; to a-&#173;wave amplitude ratio is decreased in electroretinographic bright-&#173;flash, dark-&#173;adapted testing. The CVOS showed that visual prognosis is generally poor, with only approximately 10% of eyes achieving vision better than 20/400. With anti-&#173;VEGF treatment, the prognosis may be somewhat better in all but the most ischemic cases.</p>
			<p class="body-text">Hemiret&#173;i&#173;nal vein occlusion (HRVO), which shares features with both CRVO and BRVO, has been associated with a congenital variation in central vein anatomy; it may involve &#173;either the superior or inferior half of the ret&#173;ina (<span class="xref-figure">Fig 6-12</span>).</p>
			<p class="body-text">Histologic studies suggest that most forms of CRVO share a common mechanism: thrombosis of the central ret&#173;i&#173;nal vein at or posterior to the level of the lamina cribrosa. It is postulated that, in some cases, a thickened central ret&#173;i&#173;nal artery may impinge on the central ret&#173;i&#173;nal vein, causing turbulence, endothelial damage, and thrombus formation. When thrombosis is more anterior, fewer collaterals are available, resulting in greater ischemia.</p>
			<p class="h3">Iris neovascularization in CRVO</p>
			<p class="body-text--no-indent-">Among eyes with severely ischemic CRVO, the incidence of anterior segment neovascularization, iris and &#173;angle, is high (up to 60%); this development occurs on average 3–5 months &#173;after the onset of symptoms. If not detected promptly, neovascular glaucoma may develop. The CVOS found that poor visual acuity is the risk &#173;factor most predictive of iris neovascularization in central venous occlusive disease. Other risk &#173;factors include large areas of ret&#173;i&#173;nal capillary nonperfusion and intraret&#173;i&#173;nal blood.</p>
			<p class="reference--journal--first">Baseline and early natu&#173;ral history report. The Central Vein Occlusion Study. <span class="italic">Arch Ophthalmol.</span> 1993;111(8):1087–1095.</p>
			<p class="reference--journal--last ParaOverride-7">Klein R, Moss SE, Meuer SM, Klein BE. The 15-&#173;year cumulative incidence of ret&#173;i&#173;nal vein occlusion: the Beaver Dam Eye Study. <span class="italic">Arch Ophthalmol.</span> 2008;126(4):513–518.</p>
			<p class="h3">Risk &#173;factors and &#173;causes of CRVO</p>
			<p class="body-text--no-indent-">The most impor&#173;tant risk &#173;factor for the development of CRVO is age; 90% of patients are older than 50&#160;years at the time of onset. Mild CRVOs generally occur at a younger age. The Eye Disease Case-&#173;Control Study and other studies found the following additional risk &#173;factors associated with CRVO:</p>
			<ul>
				<li class="bullet-list-first">systemic arterial hypertension</li>
				<li class="bullet-list-mid">open-&#173;angle glaucoma</li>
				<li class="bullet-list-mid">diabetes mellitus</li>
				<li class="bullet-list-mid">hyperlipidemia</li>
				<li class="bullet-list-last">hypercoagulability</li>
			</ul>
			<p class="body-text">It is common for patients presenting with CRVO to have elevated intraocular pressure (IOP) or frank open-&#173;angle glaucoma, &#173;either only in the affected eye or in both eyes; if CRVO is pres&#173;ent in 1 eye, it is impor&#173;tant to assess the fellow eye for glaucoma. CRVO can also lead to a transient shallowing of the anterior chamber that, in some instances, leads to angle-&#173;closure glaucoma.</p>
			<p class="body-text">Oral contraceptives and diuretics have been implicated as risk &#173;factors for the development of CRVO. Although rare, predisposing hypercoagulable conditions may be pres&#173;ent; &#173;these abnormalities include hyperhomocysteinemia, protein S deficiency, protein C deficiency, and disorders associated with vasculitis such as sarcoidosis and systemic lupus erythematosus. However, when CRVO occurs in patients older than 50&#160;years, it is generally considered unnecessary to pursue an elaborate systemic workup.</p>
			<p class="h3">Differential diagnosis of CRVO</p>
			<p class="body-text--no-indent-">It is particularly impor&#173;tant to recognize that <span class="italic">hyperviscosity retinopathy</span> can mimic a typical CRVO. However, the ret&#173;i&#173;nal findings in hyperviscosity retinopathy are generally bilateral and are usually related to dysproteinemia, for example, that associated with Waldenstr<span class="accent">ö</span>m macroglobulinemia, multiple myeloma, or blood dyscrasias (eg, polycythemia vera). In many cases, the hyperviscosity can be reversed by treating the under&#173;lying condition. To assess for &#173;these conditions, diagnostic testing may include complete blood count, serum protein electrophoresis, and a mea&#173;sure of whole-&#173;blood viscosity. <span class="italic">Ocular ischemic syndrome</span> can also mimic CRVO, but hemorrhages are limited to the deeper ret&#173;i&#173;nal layers and vascular tortuosity is absent. Unusual diseases that affect the blood vessel wall, blood-&#173;clotting mechanisms, or blood viscosity may also produce a CRVO-&#173;like picture.</p>
			<p class="reference--journal--first">Central Vein Occlusion Study Group. Natu&#173;ral history and clinical management of central ret&#173;i&#173;nal vein occlusion. <span class="italic">Arch Ophthalmol.</span> 1997;115(4):486–491.</p>
			<p class="reference--non-journal--last ParaOverride-7">Fuller JJ, Mason JO III. Ret&#173;i&#173;nal vein occlusions: update on diagnostic and therapeutic advances. <span class="italic">Focal Points: Clinical Modules for Ophthalmologists.</span> San Francisco: American Acad&#173;emy of Ophthalmology; 2007, module 5.</p>
			<p class="h3">Evaluation and management of CRVO</p>
			<p class="body-text--no-indent-">To determine &#173;whether the vein occlusion is nonischemic or ischemic, the examiner should assess the patient’s visual acuity, visual fields, and relative afferent defect via ophthalmoscopy, fluorescein angiography, OCT, and electroretinography. It is impor&#173;tant to perform gonioscopy regularly during follow-up to check for &#173;angle neovascularization.</p>
			<p class="body-text">If the evaluation indicates that common risk &#173;factors for CRVO are absent, or if the patient is less than 50&#160;years of age, a thorough investigation should be considered, possibly including a workup for thrombophilia.</p>
			<p class="body-text">Patients with CRVO should be warned about the possibility of worsening vision; eyes that initially appear perfused sometimes develop progressive ischemia. During the CVOS, 16% of initially nonischemic CRVOs converted to ischemia by 4 months of follow-&#173;up; by 36 months, the percentage had increased to 34%.</p>
			<p class="h4-text"><span class="h4-head">Follow-&#173;up</span> In the absence of treatment, patients with CRVO should be monitored monthly during the first 6 months for evidence of progression and development of anterior segment neovascularization or neovascular glaucoma. Patients treated with anti-&#173;VEGF agents should be observed for a similar duration &#173;after discontinuation of the drugs.</p>
			<p class="h4-text"><span class="h4-head">Complications</span> The most common complications of CRVO are vitreous hemorrhage, anterior segment neovascularization, and neovascular glaucoma. Vitreous hemorrhage may occur in the absence of obvious neovascularization, and neovascular glaucoma can occur from &#173;angle neovascularization with or without iris neovascularization.</p>
			<p class="reference--journal--single">Stem MS, Talwar N, Comer GM, Stein JD. A longitudinal analy&#173;sis of risk &#173;factors associated with central ret&#173;i&#173;nal vein occlusion. <span class="italic">Ophthalmology.</span> 2013;120(2):362–370.</p>
			<p class="h3">Treatment of CRVO</p>
			<p class="h4-text ParaOverride-11"><span class="h4-head">Pharmacologic management</span> Pharmacologic management is currently the mainstay of RVO management. See the section Pharmacologic Management of Ret&#173;i&#173;nal Vein Occlusion for a discussion of this topic.</p>
			<p class="h4-text"><span class="h4-head">Surgical management of CRVO</span></p>
			<p class="h5-text ParaOverride-11"><span class="h5-head">macular &#173;laser surgery</span> The CVOS demonstrated that grid pattern &#173;laser in CRVO with macular edema does not improve visual acuity and is therefore not recommended.</p>
			<p class="h5-text"><span class="h5-head">panret&#173;i&#173;nal photocoagulation</span> The CVOS found that prophylactic panret&#173;i&#173;nal photocoagulation (PRP) did not result in a statistically significant decrease in the incidence of iris neovascularization. In fact, 20% of participants who received the prophylactic PRP still developed iris neovascularization. Therefore, patients at high risk of iris neovascularization should be closely monitored. Although the CVOS investigators recommended waiting &#173;until an undilated gonioscopic examination revealed at least 2 clock-&#173;hours of iris neovascularization before performing PRP, in clinical practice PRP is often performed at the first sign of iris neovascularization, particularly when close follow-up is not pos&#173;si&#173;ble or seems unlikely. Wide-&#173;field angiography provides expanded visualization of peripheral nonperfusion in CRVO; however, &#173;there is no evidence to support altered treatment criteria based on this information.</p>
			<p class="reference--journal--single">Central Vein Occlusion Study Group. A randomized clinical trial of early panret&#173;i&#173;nal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. <span class="italic">Ophthalmology.</span> 1995;102(10):1434–1444.</p>
			<p class="h5-text"><span class="h5-head">pars plana vitrectomy</span> CRVOs complicated by vitreous hemorrhage may benefit from pars plana vitrectomy. Vitrectomy is used for vision rehabilitation or to accomplish ret&#173;i&#173;nal ablative treatment in the management of anterior segment neovascularization and neovascular glaucoma. For neovascular glaucoma, a glaucoma valve may be implanted concurrently.</p>
			<p class="h5-text"><span class="h5-head">other surgical approaches</span> Several surgical approaches have been abandoned due to lack of evidence for their efficacy and/or their high complication rates. &#173;These approaches include creation of peripheral &#173;laser anastomosis between a ret&#173;i&#173;nal vein and the choroidal circulation, radial relaxing incision of the optic nerve scleral ring to decompress the central ret&#173;i&#173;nal vein, and ret&#173;i&#173;nal vein cannulation with infusion of tissue plasminogen activator (tPA).</p>
			<p class="h2 ParaOverride-15">Pharmacologic Management of Ret&#173;i&#173;nal Vein Occlusion</p>
			<p class="body-text--no-indent-">Pharmacologic management has become the mainstay treatment of CME secondary to RVO. &#173;Because studies are increasingly not separating BRVO and CRVO when evaluating pharmacologic treatment of macular edema secondary to ret&#173;i&#173;nal venous occlusive disease, they are discussed together in this section.</p>
			<p class="h3">Intravitreal anti-&#173;VEGF therapy</p>
			<p class="body-text--no-indent-">The initial studies of anti-&#173;VEGF therapy of RVO &#173;were BRAVO (Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Ret&#173;i&#173;nal Vein Occlusion) and CRUISE (Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Ret&#173;i&#173;nal Vein Occlusion). In &#173;these studies, monthly injections of &#173;either 0.5-&#173; or 0.3-mg <span class="italic">ranibizumab</span> or sham injections &#173;were administered for the treatment of macular edema secondary to venous occlusions. At 6 months, 15 or more ETDRS letters &#173;were gained in BRAVO in 61.1%, 55.2%, and 28.8% of eyes treated with 0.5-&#173; or 0.3-mg <span class="italic">ranibizumab</span> or sham injection, respectively; in CRUISE, the letters &#173;were gained in 47.7%, 46.2%, and 16.9% of eyes.</p>
			<p class="body-text">Similar results &#173;were achieved with intravitreal <span class="italic">aflibercept</span> (also called <span class="italic">VEGF-&#173;Trap</span>) in the VIBRANT (Study to Assess the Clinical Efficacy and Safety of VEGF Trap-&#173;Eye in Patients With Branch Ret&#173;i&#173;nal Vein Occlusion), COPERNICUS (Vascular Endothelial Growth &#173;Factor Trap-&#173;Eye: Investigation of Efficacy and Safety in Central Ret&#173;i&#173;nal Vein Occlusion; conducted within North Amer&#173;i&#173;ca), and GALILEO (similar protocol, but conducted outside North Amer&#173;i&#173;ca) studies. The benefits &#173;were maintained during the second 6&#160;months of &#173;these aflibercept studies, during which as-&#173;needed treatment was administered.</p>
			<p class="body-text">B<span class="italic">evacizumab</span> is also effective for the management of CME secondary to RVO, as demonstrated in several controlled and uncontrolled studies (<span class="xref-figure">Fig 6-13</span>). In SCORE2 (Study of Comparative Treatments for Ret&#173;i&#173;nal Vein Occlusion 2) bevacizumab was shown to be noninferior to aflibercept in the treatment of macular edema secondary to CRVO. In CRAVE (Comparison of Anti-&#173;VEGF Agents in the Treatment of Macular Edema from Ret&#173;i&#173;nal Vein Occlusion), the 98 patients who &#173;were randomized to receive &#173;either monthly bevacizumab or ranibizumab treatment for macular edema secondary to CRVO and BRVO showed no significant differences in central foveal thickness reduction or visual acuity improvement. As a result of &#173;these comparative efficacy studies and the general clinical impression of the equivalency of the anti-&#173;VEGF agents in the treatment of RVO, many prac&#173;ti&#173;tion&#173;ers use the 3 anti-&#173;VEGF drugs interchangeably. In practice, anti-&#173;VEGF agent administration strategies for RVO treatment include monthly dosing, as-&#173;needed treatment, and treat-&#173;and-&#173;extend approaches.</p>
			<p class="reference--journal--single">Brown DM, Campochiaro PA, Bhisitkul RB, et&#160;al. Sustained benefits from ranibizumab for macular edema following branch ret&#173;i&#173;nal vein occlusion: 12-&#173;month outcomes of a phase III study. <span class="italic">Ophthalmology.</span> 2011;118(8):1594–1602.</p>
			<p class="reference--journal--mid">Campochiaro PA, Brown DM, Awh CC, et&#160;al. Sustained benefits from ranibizumab for macular edema following central ret&#173;i&#173;nal vein occlusion: twelve-&#173;month outcomes of a phase III study. <span class="italic">Ophthalmology.</span> 2011;118(10):2041–2049.</p>
			<p class="reference--journal--last ParaOverride-7">Scott IU, VanVeldhuisen PC, Ip MS, et&#160;al; SCORE2 Investigator Group. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central ret&#173;i&#173;nal vein occlusion: the SCORE2 randomized clinical trial. <span class="italic">JAMA.</span> 2017;317(20):<br />2072–2087.</p>
			<p class="h3">Intravitreal corticosteroids</p>
			<p class="body-text--no-indent-">Intravitreal corticosteroids &#173;were the first pharmacological therapy that appeared efficacious for retinal vein occlusion; however, their specific risks include cataract formation (common) and steroid-&#173;induced elevation of IOP (in 20%–65% of individuals). When making patient care decisions, clinicians must weigh &#173;these risks against the benefits as well as any available alternative treatments. SCORE (Standard Care Versus Corticosteroid for Ret&#173;i&#173;nal Vein Occlusion) found that <span class="italic">intravitreal triamcinolone</span> injection in eyes with BRVO was comparable in efficacy to macular grid &#173;laser treatment with re&#173;spect to 3 or more lines of visual acuity gain. &#173;Because eyes receiving triamcinolone &#173;were more likely to develop a cataract or experience elevated IOP, the study investigators concluded that macular grid &#173;laser therapy remained the benchmark against which other treatments should be compared. In the CRVO arm of the SCORE study, at 1 year follow-up, 27% of eyes treated with 1&#160;mg of <span class="italic">triamcinolone</span> and 26% of eyes treated with 4&#160;mg of triamcinolone had improved by 15 ETDRS letters or more, compared with 7% of eyes in the observation group.</p>
			<p class="body-text">The GENEVA study (Randomized, Sham-&#173;Controlled Trial of Dexamethasone Intravitreal Implant in Patients With Macular Edema due to Ret&#173;i&#173;nal Vein Occlusion) explored the use of a <span class="italic">dexamethasone</span> (0.7-mg) intravitreal implant to treat macular edema secondary to venous occlusive disease. A statistically significant 15-&#173;letter or more improvement from baseline corrected distance visual acuity (CDVA) was achieved between 30 and 90&#160;days, with the greatest response (29%) at day 60. At day 180, &#173;there was no longer a significant difference between the sham (18%) and treatment groups (22% for the <span class="italic">dexamethasone</span> 0.7&#160;mg group). The COMRADE (Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Ret&#173;i&#173;nal Vein Occlusion) study compared the dexamethasone (0.7-mg) implant with monthly ranibizumab treatment. At the first 3 monthly follow-up visits, the efficacy of the two treatments was similar; however, at months 4–6, the eyes treated with ranibizumab had significantly better visual acuity scores, and at month 6, the mean ETDRS letters gained for the ranibizumab group and the dexamethasone (0.7-mg) implant group &#173;were 12.86 versus 2.96 letters, respectively (<span class="italic">P</span> <span class="symbol">&lt;</span> .001).</p>
			<p class="reference--journal--first ParaOverride-16">Haller JA, Bandello F, Belfort R Jr, et&#160;al; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to ret&#173;i&#173;nal vein occlusion. <span class="italic">Ophthalmology.</span> 2010;117(6):1134–1146.</p>
			<p class="reference--journal--mid">Hoerauf H, Feltgen N, Weiss C, et&#160;al; COMRADE-&#173;C Study Group. Clinical efficacy and safety of ranibizumab versus dexamethasone for central ret&#173;i&#173;nal vein occlusion (COMRADE C): a Eu&#173;ro&#173;pean label study. <span class="italic">Am J Ophthalmol.</span> 2016;169:258–267.</p>
			<p class="reference--journal--last ParaOverride-7">Scott IU, Ip MS, VanVeldhuisen PC, et&#160;al; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch ret&#173;i&#173;nal vein occlusion: the Standard Care vs Corticosteroid for Ret&#173;i&#173;nal Vein Occlusion (SCORE) study report 6. <span class="italic">Arch Ophthalmol.</span> 2009;127(9):1115–1128.</p>
			<p class="h3 ParaOverride-8">Systemic anticoagulation</p>
			<p class="body-text--no-indent-">Systemic anticoagulation is not recommended for the treatment of RVO. Case series suggest the patient may experience worse outcomes due to increased bleeding in the ret&#173;i&#173;na.</p>
			</div>
			<p class="h1">Ocular Ischemic Syndrome and Retinopathy of Carotid Occlusive Disease</p>
			<div id="Chapt6_Top3">
			<p class="body-text--no-indent-"><span class="italic">Ocular ischemic syndrome</span> (OIS) comprises the ocular symptoms and signs attributable to chronic severe ocular hypoperfusion caused by ipsilateral carotid obstruction or ophthalmic artery obstruction.</p>
			<p class="h2">Symptoms and Signs of Ocular Ischemic Syndrome</p>
			<p class="body-text--no-indent-">Symptoms of OIS typically include gradual vision loss that develops over a period of weeks to months, aching pain localized to the orbital area of the affected eye, and prolonged vision recovery &#173;after exposure to bright light. Anterior segment signs include iris neovascularization in two-&#173;thirds of eyes and an anterior chamber cellular response in about one-&#173;fifth of eyes. Although iris and &#173;angle neovascularization are common, only one-&#173;half of eyes with this condition show an increase in IOP; the low or normal IOP in the other half is most likely caused by impaired aqueous production.</p>
			<p class="body-text">Ocular ischemic syndrome can cause a retinopathy similar in appearance to a partial occlusion of the central ret&#173;i&#173;nal vein; therefore, it was originally called venous stasis retinopathy. Typical ret&#173;i&#173;nal findings include narrowed arteries, dilated but not very tortuous veins, hemorrhages, microaneurysms, and neovascularization of the optic nerve head, ret&#173;ina, or both (<span class="xref-figure">Fig 6-14</span>). The ret&#173;i&#173;nal hemorrhages in carotid occlusive disease are usually deep and round and are more often located in the midperipheral ret&#173;ina. A helpful method for differentiating between the 2 entities is to mea&#173;sure the ret&#173;i&#173;nal artery pressure, &#173;either by using an ophthalmodynamometer, or by &#173;gently pushing on the eye during the examination and observing the central ret&#173;i&#173;nal artery. An eye with CRVO &#173;will have normal artery pressure, whereas one with carotid occlusive disease &#173;will have low artery pressure, and the artery &#173;will therefore collapse easily.</p>
			<p class="body-text">Fluorescein angiography reveals delayed choroidal filling in 60% of eyes, prolonged arteriovenous transit time in 95% of eyes, and prominent vascular staining (particularly of the arteries) in 85% of eyes. Electroretinography demonstrates global amplitude reduction in disorders that affect the blood supply to the photoreceptors as well as the inner ret&#173;ina. An electronegative electroretinogram occurs if the blood supply to the inner ret&#173;ina is compromised as in CRVO or central ret&#173;i&#173;nal artery occlusion (CRAO), while supply to the photoreceptors is preserved.</p>
			<p class="h2">Etiology and Course of Ocular Ischemic Syndrome</p>
			<p class="body-text--no-indent-">The most common etiology of OIS is atherosclerosis; other pos&#173;si&#173;ble &#173;causes include Eisenmenger syndrome, &#173;giant cell arteritis (GCA), and other inflammatory conditions. Most patients are older than 55&#160;years. Typically, a 90% or greater ipsilateral obstruction is necessary to cause OIS. Approximately 20% of cases involve both eyes.</p>
			<p class="body-text">The visual prognosis for eyes with OIS is uncertain, but when rubeosis iridis is also pres&#173;ent, visual acuity in more than 90% of cases &#173;will decline to 20/200 or worse within 1&#160;year &#173;after diagnosis. For this reason, timely diagnosis is essential.</p>
			<p class="body-text">Approximately one-&#173;half of patients with OIS also have ischemic cardiovascular disease; one-&#173;fourth have had a previous cerebrovascular accident; and one-&#173;fifth have peripheral atherosclerotic vascular disease so severe that a previous surgical procedure was necessary. The stroke rate is higher than that of the general population, and the 5-&#173;year mortality is approximately 40%, mostly resulting from complications of cardiovascular disease.</p>
			<p class="h2">Treatment of Ocular Ischemic Syndrome</p>
			<p class="body-text--no-indent-">The most definitive treatment for OIS appears to be carotid artery stenting and endarterectomy, although visual acuity outcomes are variable. Unfortunately, &#173;these procedures are in&#173;effec&#173;tive when &#173;there is 100% obstruction, which is often the case. Extracranial to intracranial bypass surgery has been attempted but has been shown to be in&#173;effec&#173;tive for preventing loss of vision or stroke. In eyes with iris neovascularization and low or normal IOP as a result of impaired ciliary body perfusion and decreased aqueous formation, carotid reperfusion can lead to increased aqueous formation and a severe rise in IOP. Full-&#173;scatter PRP results in regression of anterior segment neovascularization in approximately two-&#173;thirds of cases. Anti-&#173;VEGF therapy has also been shown to cause regression of anterior segment neovascularization in patients with OIS.</p>
			<p class="reference--journal--single">Brown GC, Sharma&#160;S. Ocular ischemic syndrome. In: Schachat AP, Wilkinson CP, Hinton DR, Sadda SR, Wiedemann P, eds. <span class="italic">Ryan’s</span> <span class="italic">Ret&#173;i&#173;na.</span> 6th&#160;ed. Philadelphia: Elsevier/Saunders; 2018:chap 62.</p>
			</div>
			<p class="h1 ParaOverride-2">Arterial Occlusive Disease</p>
			<div id="Chapt6_Top4">
			<p class="body-text--no-indent-">The blood supply to the inner layers of the ret&#173;ina is derived entirely from the central ret&#173;i&#173;nal artery, &#173;unless a cilioret&#173;i&#173;nal artery is pres&#173;ent (20%–25% of eyes). Ret&#173;i&#173;nal ischemia results from disease pro&#173;cesses that affect the vessels anywhere from the common carotid artery to the intraret&#173;i&#173;nal arterioles. The signs and symptoms of arterial obstruction depend on the vessel involved: occlusion of a peripheral arteriole may be asymptomatic, whereas an ophthalmic artery occlusion can cause total blindness.</p>
			<p class="h2">Capillary Ret&#173;i&#173;nal Arteriole Obstruction (Cotton-&#173;Wool Spots)</p>
			<p class="body-text--no-indent-">Acute obstruction in the distribution of the radial peripapillary capillary net leads to the formation of a nerve fiber layer (NFL) infarct, or cotton-&#173;wool spot, which &#173;causes impaired axoplasmic transport in the NFL (<span class="xref-figure">Fig 6-15</span>). &#173;These inner ret&#173;i&#173;nal ischemic spots are superficial, white, and typically one-&#173;fourth optic disc area or less in size. They usually fade in 5–7 weeks, although spots pres&#173;ent in association with diabetic retinopathy often remain longer. A subtle ret&#173;i&#173;nal depression caused by inner ret&#173;i&#173;nal ischemic atrophy may develop in an area of prior ischemia. The effect on visual function, including loss of visual acuity and field defects, is related to the size and location of the occluded area.</p>
			<p class="body-text">The most common cause of cotton-&#173;wool spots is diabetic retinopathy (discussed in <span class="xref-local">Chapter&#160;5</span>). Other &#173;causes include</p>
			<ul>
				<li class="bullet-list-first">systemic arterial hypertension</li>
				<li class="bullet-list-mid">HIV-&#173;associated retinopathy</li>
				<li class="bullet-list-mid">anemia (severe)</li>
				<li class="bullet-list-mid">radiation retinopathy</li>
				<li class="bullet-list-mid">sickle cell retinopathy</li>
				<li class="bullet-list-mid">cardiac embolic disease</li>
				<li class="bullet-list-mid">carotid artery obstructive disease</li>
				<li class="bullet-list-mid">vasculitis</li>
				<li class="bullet-list-mid">collagen vascular disease</li>
				<li class="bullet-list-last">leukemia</li>
			</ul>
			<p class="body-text--no-indent-">If even 1 cotton-&#173;wool spot is discovered in the fundus in an other&#173;wise apparently healthy eye, the clinician should initiate a workup for the most likely under&#173;lying etiologies.</p>
			<p class="reference--journal--single">Brown GC, Brown MM, Hiller T, Fischer D, Benson WE, Magargal LE. Cotton-&#173;wool spots. <span class="italic">Ret&#173;i&#173;na.</span> 1985;5(4):206–214.</p>
			<p class="h2">Branch Ret&#173;i&#173;nal Artery Occlusion</p>
			<p class="body-text--no-indent-">Although an acute BRAO may be subtle and unapparent on initial ophthalmoscopic examination, within hours to days, it can lead to edematous opacification caused by infarction of the inner ret&#173;ina in the distribution of the affected vessel (<span class="xref-figure">Fig 6-16</span>). In time, the occluded vessel recanalizes, perfusion returns, and the edema resolves; however, a permanent visual field defect remains. A ret&#173;i&#173;nal arterial occlusion that occurs outside of the posterior pole may be clinically asymptomatic.</p>
			<p class="body-text">Occlusion at any site is caused by embolization or thrombosis of the affected vessel. &#173;There are 3 main va&#173;ri&#173;e&#173;ties of emboli:</p>
			<p class="numbered-list-first">1.&#9;cholesterol emboli (Hollenhorst plaques) arising in the carotid arteries (<span class="xref-figure">Fig 6-17</span>)</p>
			<p class="numbered-list-mid">2.&#9;platelet-&#173;fibrin emboli associated with large-&#173;vessel arteriosclerosis</p>
			<p class="numbered-list-last">3.&#9;calcific emboli arising from diseased cardiac valves</p>
			<p class="body-text--no-indent-">In rare cases, emboli might be caused by cardiac myxoma, long-&#173;bone fractures (fat emboli), infective endocarditis (septic emboli), and intravenous drug use (talc emboli). Although rare, migraine can cause ocular arterial occlusions in patients younger than 30–40&#160;years. Other pos&#173;si&#173;ble &#173;causes of emboli include</p>
			<ul>
				<li class="bullet-list-first ParaOverride-10">arrhythmias</li>
				<li class="bullet-list-mid">mitral valve prolapse</li>
				<li class="bullet-list-mid">oral contraceptive use or pregnancy</li>
				<li class="bullet-list-mid">coagulation disorders</li>
				<li class="bullet-list-mid">trauma</li>
				<li class="bullet-list-mid">sickle cell disease</li>
				<li class="bullet-list-mid">inflammatory and infectious etiologies such as toxoplasmic retinochoroiditis and syphilis</li>
				<li class="bullet-list-last ParaOverride-17">connective tissue disorders, including GCA</li>
			</ul>
			<p class="body-text">Initial management is directed &#173;toward determining the under&#173;lying systemic etiologic &#173;factors. Ret&#173;i&#173;nal arterial occlusions should be referred <span class="italic">urgently</span> to an emergency department for a stroke workup. No specific ocular therapy has been found to be consistently effective in improving the visual prognosis. Lowering IOP and applying intermittent pressure on the globe (“ocular massage”) may dislodge an embolus from a large central vessel &#173;toward a more peripheral location, but the efficacy of &#173;these maneuvers in improving vision outcomes is unknown.</p>
			<p class="reference--journal--first ParaOverride-5">Hayreh SS, Podhajsky PA, Zimmerman MB. Branch ret&#173;i&#173;nal artery occlusion: natu&#173;ral history of visual outcome. <span class="italic">Ophthalmology.</span> 2009;116(6):1188–1194.</p>
			<p class="reference--journal--last ParaOverride-7">Wang JJ, Cugati S, Knudtson MD, et&#160;al. Ret&#173;i&#173;nal arteriolar emboli and long-&#173;term mortality: pooled data analy&#173;sis from two older populations. <span class="italic">Stroke.</span> 2006;37(7):1833–1836.</p>
			<p class="h2">Cilioretinal Artery Occlusion</p>
			<p class="body-text--no-indent-">A distinct clinical entity is the occlusion of the cilioret&#173;i&#173;nal artery, which arises from the short posterior ciliary vessels rather than the central ret&#173;i&#173;nal artery. &#173;These vessels, which are pres&#173;ent in about 18%–32% of eyes, usually contribute to some portion of the macular circulation. Most commonly, their occlusion occurs in patients with a central ret&#173;i&#173;nal vein occlusion; it is postulated that the increased hydrostatic pressure associated with CRVO can reduce blood flow in the cilioret&#173;i&#173;nal artery to the point of stagnation.</p>
			<p class="body-text">When cilioret&#173;i&#173;nal artery occlusion occurs in isolation, GCA should be considered.</p>
			<p class="reference--journal--single ParaOverride-5">Hayreh SS, Fraterrigo L, Jonas&#160;J. Central ret&#173;i&#173;nal vein occlusion associated with cilioret&#173;i&#173;nal artery occlusion. <span class="italic">Ret&#173;i&#173;na.</span> 2008;28(4):581–594.</p>
			<p class="h2 ParaOverride-15">Paracentral Acute &#173;Middle Maculopathy</p>
			<p class="body-text--no-indent-">Paracentral acute &#173;middle maculopathy (PAMM) refers to acute ischemic events that affect the deep macular capillary layers. It is best visualized as hyperreflective bands on SD-&#173;OCT. &#173;There are 2 variants: type 1 affects the superficial capillary plexus in the outer plexiform layer (OPL)/inner nuclear layer (INL) region, and type 2 affects the deep capillary plexus in the OPL/outer nuclear layer (ONL) region. Visual consequences vary; upon resolution, type 1 lesions produce INL thinning, and type 2 lesions cause disturbance of the ellipsoid or inner segment and outer segment line.</p>
			<p class="reference--journal--single ParaOverride-5">Sarraf D, Rahimy E, Fawzi AA, et&#160;al. Paracentral acute &#173;middle maculopathy: a new variant of acute macular neuroretinopathy associated with ret&#173;i&#173;nal capillary ischemia. <span class="italic">JAMA Ophthalmol.</span> 2013;131(10):1275–1287.</p>
			<p class="h2 ParaOverride-15">Central Ret&#173;i&#173;nal Artery Occlusion</p>
			<p class="body-text--no-indent-">Sudden, complete, and painless loss of vision in one eye is characteristic of CRAO. The ret&#173;ina becomes opaque and edematous, particularly in the posterior pole, where the nerve fiber and ganglion cell layers are thickest (<span class="xref-figure">Fig 6-18</span>). The orange reflex from the intact choroidal vasculature beneath the foveola thus stands out in contrast to the surrounding opaque neural ret&#173;ina, producing a cherry-&#173;red spot. Even prior to the appearance of the cherry-&#173;red spot, OCT imaging reveals a normal macular profile with diffuse hyperreflectivity and loss of internal layer definition (<span class="xref-table">Activity 6-2; Fig 6-19</span>). A cilioret&#173;i&#173;nal artery may preserve some degree of macular vision if the area of ret&#173;ina perfused by it includes a sufficient portion of the maculopapillary bundle as well as the perifovea (see <span class="xref-figure-local">Chapter&#160;1, Fig 1</span>-&#173;<span class="xref-figure-local">8</span>).</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer004" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first-recto ParaOverride-18">  <span class="QR-code-activity-number">ACTIVITY 6-2</span> OCT Activity: SD-&#173;OCT scan of an eye with CRAO <br />and cilioret&#173;i&#173;nal artery sparing.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer006" class="_idGenObjectStyleOverride-1">
					<div id="_idContainer005" class="_idGenObjectStyleOverride-1">
						<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
					</div>
				</div>
			</div>
			<p class="activity-source-recto ParaOverride-19">Courtesy of Colin&#160;A. McCannel, MD.</p>
			<p class="body-text">With time, the central ret&#173;i&#173;nal artery reopens or recanalizes and the ret&#173;i&#173;nal edema clears; however, the effect on visual acuity is usually permanent &#173;because the inner ret&#173;ina has been infarcted. In one study, 66% of eyes had final visual acuity worse than 20/400, and 18% of eyes had 20/40 or better. Most cases of 20/40 or better visual acuity occur in the presence of a patent cilioret&#173;i&#173;nal artery (see Fig 6-18; also see <span class="xref-figure-local">Chapter&#160;1, Fig 1</span>-&#173;<span class="xref-figure-local">8</span>). Vaso-&#173;occlusive vision loss to the level of no light perception is usually caused by choroidal vascular insufficiency from partial or complete ophthalmic artery occlusion or occlusions of the ciliary arteries in conjunction with occlusion of the central ret&#173;i&#173;nal artery (<span class="xref-figure">Fig 6-20</span>). Studies in nonhuman primates have suggested that irreversible damage to the sensory ret&#173;ina occurs &#173;after 90 minutes of complete CRAO. Nevertheless, clinical return of vision can occur in some instances even if the obstruction has persisted for many hours.</p>
			<p class="body-text">CRAO is most often caused by embolization or atherosclerosis-&#173;related thrombosis occurring at the level of the lamina cribrosa. Less common &#173;causes are hemorrhage &#173;under an atherosclerotic plaque, thrombosis, trauma, spasm, and a dissecting aneurysm within the central ret&#173;i&#173;nal artery.</p>
			<p class="body-text">Emboli within the carotid distribution may cause transient ischemic attacks, amaurosis fugax, or both. Bright cholesterol emboli, or Hollenhorst plaques, typically located at ret&#173;i&#173;nal arterial bifurcations, suggest a carotid atheromatous origin and may be an indication for endarterectomy if accompanied by relevant symptoms and findings. Systemic etiologic considerations, such as &#173;those listed earlier in this chapter for BRAO, are impor&#173;tant and require evaluation. The leading cause of death in patients with ret&#173;i&#173;nal arterial obstruction is cardiovascular disease with an elevated risk of myo&#173;car&#173;dial infarction within the first 7 days following onset of the obstruction. Immediate referral for brain imaging in a stroke center is indicated, along with evaluation of the carotid arteries via Doppler ultrasound or computed tomography angiography (CTA) and of the cardiac valves via transesophageal echocardiography. Callizo studies have reported that as many as 78% of patients may have undiagnosed risk &#173;factors.</p>
			<p class="body-text">GCA accounts for approximately 1%–2% of CRAO cases. In cases of CRAO in which emboli are not readily vis&#173;i&#173;ble, a thorough evaluation for GCA should be considered. The risk of GCA increases with increasing age. The erythrocyte sedimentation rate (ESR), C-&#173;reactive protein level, and fibrinogen levels—&#173;markers of inflammation—&#173;are usually elevated and should be checked. A complete blood count may detect an elevated platelet count, which is also suggestive of GCA; the blood count also aids in the interpretation of the ESR. If GCA is suspected as a cause, corticosteroid therapy should be instituted promptly &#173;because the second eye can become involved by ischemia within hours to days &#173;after the first. In addition, a temporal artery biopsy should be performed shortly thereafter to confirm the diagnosis and justify the need for prolonged corticosteroid treatment. See BCSC Section&#160;5, <span class="italic">Neuro-&#173;Ophthalmology,</span> for further discussion of GCA.</p>
			<p class="reference--journal--first">Ahn SJ, Woo SJ, Park KH, Jung C, Hong JH, Han MK. Ret&#173;i&#173;nal and choroidal changes and visual outcome in central ret&#173;i&#173;nal artery occlusion: an optical coherence tomography study. <span class="italic">Am J Ophthalmol.</span> 2015;159(4):667–676.</p>
			<p class="reference--journal--mid">Atkins EJ, Bruce BB, Newman NJ, Biousse&#160;V. Translation of clinical studies to clinical practice: survey on the treatment of central ret&#173;i&#173;nal artery occlusion. <span class="italic">Am J Ophthalmol.</span> 2009;148(1):172–173.</p>
			<p class="reference--journal--mid">Callizo J, Feltgen N, Pantenburg S, et&#160;al; Eu&#173;ro&#173;pean Assessment Group for Lysis in the Eye. Cardiovascular risk &#173;factors in central ret&#173;i&#173;nal artery occlusion: results of a prospective <br />and standardized medical examination. <span class="italic">Ophthalmology.</span> 2015;122(9):1881–1888.</p>
			<p class="reference--journal--mid">Falkenberry SM, Ip MS, Blodi BA, Gunther JB. Optical coherence tomography findings <br />in central ret&#173;i&#173;nal artery occlusion. <span class="italic">Ophthalmic Surg &#173;Lasers Imaging.</span> 2006;37(6):<br />502–505.</p>
			<p class="reference--journal--last ParaOverride-7">Park SJ, Choi NK, Yang BR, et&#160;al. Risk and risk periods for stroke and acute myo&#173;car&#173;dial infarction in patients with central ret&#173;i&#173;nal artery occlusion. <span class="italic">Ophthalmology.</span> 2015;122(11):<br />2336–2343.</p>
			<p class="h3">Management of CRAO</p>
			<p class="body-text--no-indent-">If therapy for CRAO is to be instituted, it should be undertaken without delay. Unfortunately, treatment is effective in only a small fraction of cases. &#173;Simple therapeutic approaches, such as reducing IOP by administering IOP-&#173;lowering medi&#173;cations and performing ocular massage, are not without benefit. However, outcomes from both anterior chamber paracentesis and carbogen (a mixture of 95% oxygen and 5% carbon dioxide) vasodilatory inhalation therapy have shown inconsistent success, as have hyperbaric oxygen therapy, catheterization of the ophthalmic artery with tPA infusion, and transvitreal Nd:YAG embolysis. Initial management should also include an evaluation directed &#173;toward determining the under&#173;lying systemic etiologic &#173;factors, and an <span class="italic">urgent</span> referral to an emergency department for a stroke workup should be undertaken.</p>
			<p class="body-text">Iris neovascularization develops in approximately 18% of eyes within 1–12 weeks &#173;after acute CRAO, with a mean time interval of approximately 4–5 weeks. Full-&#173;scatter PRP results in regression of anterior segment neovascularization in approximately two-&#173;thirds of cases. Anti-&#173;VEGF therapy in conjunction with PRP has been reported to have value as well.</p>
			<p class="h2">Ophthalmic Artery Occlusion</p>
			<p class="body-text--no-indent-">Ophthalmic artery occlusion is very rare. Clinically, the disorder typically produces vision loss to the level of light perception or no light perception &#173;because simultaneous nonperfusion of the choroid and ret&#173;ina results in ischemia of all ret&#173;i&#173;nal layers. A cherry-&#173;red spot may not be pres&#173;ent; both the inner ret&#173;ina and outer ret&#173;ina become opacified from the infarction, resulting in an absence of contrast difference between foveal and perifoveal ret&#173;ina that would produce such a spot.</p>
			<p class="body-text">Ophthalmic artery occlusion may be caused by dissection of the internal carotid artery, orbital mucormycosis, or embolization. An increasing number of ophthalmic artery occlusions caused by vari&#173;ous cosmetic facial-&#173;filler injections, particularly into the periocular and brow area, have been reported, as popularity for such procedures has increased (<span class="xref-figure">Fig 6-21</span>). In autopsy studies of patients who died during active GCA, up to 76% had some degree of ophthalmic artery affected by vasculitis; clinically, however, ophthalmic artery occlusion is rare in GCA.</p>
			</div>
			<p class="h1">Arterial Macroaneurysms</p>
			<div id="Chapt6_Top5">
			<p class="body-text--no-indent-">Ret&#173;i&#173;nal arterial macroaneurysms are acquired ectasias of the first 3 &#173;orders of ret&#173;i&#173;nal arterioles. Large macroaneurysms can actually traverse the full thickness of the ret&#173;ina. Vision loss may occur from embolic or thrombotic occlusion of the end arteriole (white infarct) or from sub–&#173;internal limiting membrane, intraret&#173;i&#173;nal, subret&#173;i&#173;nal, or vitreous hemorrhage, often in combination. Other ret&#173;i&#173;nal findings may include capillary telangiectasia and remodeling, as well as ret&#173;i&#173;nal edema and exudate involving the macula (Fig 6-22). Often, &#173;there are multiple arterial macroaneurysms, although only 10% of cases are bilateral. Arterial macroaneurysms are associated with systemic arterial hypertension in about two-&#173;thirds of cases and may occur in the area of previous vascular occlusions. Sclerosis and spontaneous closure often accompany macroaneurysm-&#173;related hemorrhage; bleeding more than once is rare.</p>
			<p class="body-text">&#173;Laser photocoagulation treatment may be considered if increasing edema in the macula threatens central visual function. In most instances, moderate-&#173;intensity &#173;laser treatment of the retina—&#173;performed immediately adjacent to the macroaneurysm using 2–3 rows of large-&#173;spot-&#173;size (200–500 µm) applications—&#173;results in closure. Some specialists prefer direct treatment. Caution should be used when treating macroaneurysms that occur in macular arterioles &#173;because a primary complication of the disease and its therapy is thrombosis with ret&#173;i&#173;nal arterial obstruction distal to the macroaneurysm. Anti-&#173;VEGF treatment has been reported to hasten resolution of macular edema from macroaneurysms without improving ultimate visual outcome.</p>
			<p class="reference--journal--first">Cho HJ, Rhee TK, Kim HS, et&#160;al. Intravitreal bevacizumab for symptomatic ret&#173;i&#173;nal arterial macroaneurysm. <span class="italic">Am J Ophthalmol.</span> 2013;155(5):898–904.</p>
			<p class="reference--journal--mid">Lee EK, Woo SJ, Ahn J, Park KH. Morphologic characteristics of ret&#173;i&#173;nal arterial macroaneurysm and its regression pattern on spectral-&#173;domain optical coherence tomography. <span class="italic">Ret&#173;i&#173;na.</span> 2011;31(10):2095–2101.</p>
			<p class="reference--journal--last">Pitk<span class="accent">ä</span>nen L, Tommila P, Kaarniranta K, J<span class="accent">ää</span>skel<span class="accent">ä</span>inen JE, Kinnunen&#160;K. Ret&#173;i&#173;nal arterial macro&#173;aneurysms. <span class="italic">Acta Ophthalmol.</span> 2014;92(2):101–104.</p>
		</div>
		</div>
		<div id="_idContainer008" class="_idGenObjectStyleOverride-1">
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer011">
				<div id="_idContainer009" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/KIN00190.png" alt="" />
				</div>
				<div id="_idContainer010" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-1</span> Severe hypertensive retinopathy. <span class="figure-caption-bold">A,</span> Fundus photograph from a 25-year-old man with renal hypertension shows large superficial and white cotton-wool spots contrasting with small, tan, and deep focal intraretinal periarteriolar transudates (FIPTs). <span class="figure-caption-bold">B,</span> Angiography image shows areas of nonperfusion corresponding to the cotton-wool spots and punctuate hyperfluorescence corresponding to the FIPTs. <span class="figure-source-note">(Courtesy of Hermann D. Schubert, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer014">
				<div id="_idContainer012" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/AAX-0604.png" alt="" />
				</div>
				<div id="_idContainer013" class="Basic-Text-Frame">
					<p class="figure-caption ParaOverride-21"><span class="figure-number">Figure 6-2</span> Fundus photograph shows Elschnig spots. <span class="figure-source-note">(Courtesy of Harry W. Flynn, Jr, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer017">
				<div id="_idContainer015" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/KIN00191.png" alt="" />
				</div>
				<div id="_idContainer016" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-3</span> Malignant hypertension. <span class="figure-caption-bold">A,</span> Color fundus photograph of hypertensive retinopathy with shallow detachment of the macula, striae of the internal limiting membrane, splinter hemorrhages in the radial peripapillary net, hyperemia of the optic nerve, and a few lipid exudates in the macula. Multiple tan patches at the level of the retinal pigment epithelium (RPE) and inner choroid are due to hypertensive choroidopathy. <span class="figure-caption-bold">B,</span> Early fluorescein angiography image reveals retinal capillary nonperfusion, microaneurysms, and choroidal filling defects. <span class="figure-caption-bold">C,</span> Late angiography image shows intense vascular leakage as well as leakage from patches of hypertensive choroidopathy. <span class="figure-caption-bold">D,</span> Early indocyanine green (ICG) angiography image shows a “moth-eaten” appearance of the choriocapillaris. <span class="figure-source-note">(Courtesy of Richard Spaide, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer020">
				<div id="_idContainer018" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/KIN00117.png" alt="" />
				</div>
				<div id="_idContainer019" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-4</span> Severe hypertensive retinopathy with improvement. <span class="figure-caption-bold">A,</span> Fundus photograph of a 25-year-old patient with severe hypertension (210/140 mm Hg) and visual acuity loss to the 2/200 level. Note the optic nerve head edema, macular exudates, intraretinal hemorrhage with nerve fiber layer (NFL) infarct, and venous congestion. <span class="figure-caption-bold">B,</span> Fundus photograph of the same patient 10 weeks later, after treatment of hypertension and normalization of blood pressure. The optic nerve head is now normal, and minimal residual macular exudates are present. Visual acuity has returned to 20/50. <span class="figure-source-note">(Courtesy of Harry W. Flynn, Jr, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer023">
				<div id="_idContainer021" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/KIN00833.png" alt="" />
				</div>
				<div id="_idContainer022" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-5</span> Branch retinal vein occlusion (BRVO) with ischemia. <span class="figure-caption-bold">A,</span> Fundus photograph shows inferotemporal BRVO. <span class="figure-caption-bold">B,</span> Fluorescein angiography image corresponding to <span class="figure-caption-bold">A</span> reveals pronounced retinal capillary nonperfusion in the distribution of the retina drained by the obstructed vein. <span class="figure-caption-bold">C,</span> Spectral-domain optical coherence tomography (SD-OCT) image of the same eye reveals cystoid macular edema (CME). <span class="figure-source-note">(Courtesy of Neal H. Atebara, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer024" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/KIN00834.png" alt="" />
			</div>
		</div>
		<div id="_idContainer025" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 6-6</span> Chronic changes from nonischemic central retinal vein occlusion (CRVO) in a 30-year-old woman with a history of diabetes mellitus and blurry vision for 2 months. Visual acuity is 20/25. <span class="figure-caption-bold">A,</span> Color fundus photograph of a mild nonischemic, or perfused, CRVO. Dilated retinal veins and retinal hemorrhages are present, as are scant macular exudates inferior to fovea. <span class="figure-caption-bold">B,</span>&#160;Fluorescein angiography image taken 22 seconds after injection reveals capillary telangiectasias and microaneurysms throughout the posterior pole. <span class="figure-caption-bold">C,</span> Late angiogram taken at 9&#160;minutes reveals diffuse retinovascular leakage and microaneurysms. <span class="figure-caption-bold">D,</span> OCT scan reveals mild cystic changes and microaneurysms but minimal retinal thickening and normal foveal contour. <span class="figure-source-note">(Courtesy of Neal H. Atebara, MD.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer028">
				<div id="_idContainer026" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/KIN00125.png" alt="" />
				</div>
				<div id="_idContainer027" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-7</span> BRVO. <span class="figure-caption-bold">A,</span> Fundus photograph of inferotemporal BRVO. Corresponding fluorescein angiography images show, at 49 seconds after injection <span class="figure-caption-bold">(B),</span> telangiectatic vessels in the distribution of the inferotemporal vein, and at 393 seconds after injection <span class="figure-caption-bold">(C),</span> intraretinal leakage of dye from the capillaries in macular distribution of the vein occlusion <span class="figure-caption-italic">(white)</span>. <span class="figure-caption-bold">D,</span> Fundus photograph after treatment shows a grid of macular photocoagulation lesions in the affected area but sparing the foveal region. <span class="figure-source-note">(Courtesy of Gary C. Brown, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer031">
				<div id="_idContainer029" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/KIN00126.png" alt="" />
				</div>
				<div id="_idContainer030" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-8</span> BRVO with neovascularization. <span class="figure-caption-bold">A,</span> Neovascularization of the optic nerve head occurring secondary to a superotemporal BRVO. <span class="figure-caption-bold">B,</span> Corresponding fluorescein angiography image taken 18 seconds after injection reveals marked hyperfluorescence of the new vessels originating on the optic nerve head. <span class="figure-source-note">(Courtesy of Gary C. Brown, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer032" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/KIN00835.png" alt="" />
			</div>
		</div>
		<div id="_idContainer033" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 6-9</span> Moderate to severe nonischemic CRVO. <span class="figure-caption-bold">A,</span> Ultra-wide-field fundus photograph of moderate to severe nonischemic, or perfused, CRVO in an eye with 20/80 visual acuity. Dilated retinal veins and retinal hemorrhages are present in all 4 quadrants. Cotton-wool spots can be seen near the optic nerve head. <span class="figure-caption-bold">B,</span> A fluorescein angiography image taken at 1 minute, 8&#160;seconds reveals relatively intact perfusion of the retinal capillary bed but dilated vessels and peripheral leakage from the large vessels. There are some areas of capillary nonperfusion in the superior macula. <span class="figure-caption-bold">C,</span> An SD-OCT scan shows severe cystoid retinal edema with a serous foveal detachment. After 2.5 years of anti–vascular endothelial growth factor (VEGF) treatment with bevacizumab, the patient maintains a visual acuity of 20/40. <span class="figure-source-note">(Courtesy of Colin A. McCannel, MD.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer034" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/AAX-9936.png" alt="" />
			</div>
		</div>
		<div id="_idContainer035" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 6-10</span> Macular OCT of eye shown in Figure 6-9 demonstrates severe CME with foveal detachment. There is also mild to moderate inner retinal hyperreflectivity, consistent with some degree of ischemia. However, the fluorescein images of the retina (Fig 6-9) show that perfusion is present. <span class="figure-source-note">(Courtesy of Colin A. McCannel, MD.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer038">
				<div id="_idContainer036" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/KIN00836.png" alt="" />
				</div>
				<div id="_idContainer037" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-11</span> Ischemic CRVO. <span class="figure-caption-bold">A,</span> Ultra-wide-field fundus photograph of severe, or ischemic, CRVO in an eye with hand motions visual acuity. The veins are dilated, and extensive retinal hemorrhages are present. <span class="figure-caption-bold">B,</span> Ultra-wide-field fluorescein angiography image corresponding to <span class="figure-caption-bold">A</span> taken 40 seconds after injection reveals widespread retinal capillary nonperfusion, which causes the midsize and larger retinal vessels to stand out from the gray-black, nonperfused areas.<span class="figure-source-note"> (Courtesy of Colin A. McCannel, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer041">
				<div id="_idContainer039" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/KIN00124.png" alt="" />
				</div>
				<div id="_idContainer040" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-12</span> Hemiretinal vein occlusion. <span class="figure-caption-bold">A,</span> Fundus photograph shows superior involvement with intraretinal hemorrhage. <span class="figure-caption-bold">B,</span> Fluorescein angiography image shows blockage of underlying details in areas of hemorrhage. Note that the foveal avascular zone is largely intact.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer042" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/AAX-7580.png" alt="" />
			</div>
		</div>
		<div id="_idContainer043" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 6-13</span> CME secondary to CRVO, before and after treatment. <span class="figure-caption-bold">A,</span> SD-OCT scan shows severe CME with foveal detachment in a patient with a nonischemic CRVO. Visual acuity was 20/200. <span class="figure-caption-bold">B,</span> One month after intravitreal injection of bevacizumab, 1.25 mg, the cystic changes and foveal detachment resolved, and the visual acuity was 20/25. <span class="figure-source-note">(Courtesy of Colin A. McCannel, MD.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer046">
				<div id="_idContainer044" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/KIN00837.png" alt="" />
				</div>
				<div id="_idContainer045" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-14</span> Ocular ischemic syndrome (OIS). <span class="figure-caption-bold">A,</span> Clinical photograph of an eye with OIS displays features of conjunctival injection, cataract, and rubeosis iridis. <span class="figure-caption-bold">B,</span> Gonioscopic appear-<br />ance of neovascularization of the iridocorneal angle due to OIS. <span class="figure-caption-bold">C,</span> Fundus photograph of an eye with OIS shows features of venous dilation, midperipheral intraretinal hemorrhages, and attenuated arterioles. <span class="figure-caption-bold">D,</span> Fluorescein angiography image taken at 19 seconds (arterial phase) demonstrates a prolonged arm-to-retina circulation time and a patchy choroidal filling pattern. <span class="figure-source-note">(Courtesy of Neal H. Atebara, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer049">
				<div id="_idContainer047" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-15</span> Fundus photograph shows a cotton-wool spot. <span class="figure-source-note">(Courtesy of Gary C. Brown, MD.)</span></p>
				</div>
				<div id="_idContainer048" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/AAX-0632.jpg" alt="" />
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer052">
				<div id="_idContainer050" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/AAX-0633.jpg" alt="" />
				</div>
				<div id="_idContainer051" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-16</span> Inferotemporal branch retinal artery obstruction. The fundus photograph shows opacification of the retina in the distribution of the occluded vessel (inferior macula). In this case, the visual acuity was 20/30 at presentation but returned to 20/20 over several weeks. <span class="figure-source-note">(Courtesy of Gary C. Brown, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer055">
				<div id="_idContainer053" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/AAX-7583.png" alt="" />
				</div>
				<div id="_idContainer054" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-17</span> Hollenhorst plaque. Fundus photograph shows a Hollenhorst plaque lodged at a bifurcation of the superior arcade arteriole <span class="figure-caption-italic">(arrow)</span>. Hollenhorst plaques do not typically cause vascular obstruction and can remain at a bifurcation indefinitely. Occasionally, they can be observed to move with blood flow. <span class="figure-source-note">(Courtesy of Tara A. McCannel, MD, PhD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer058">
				<div id="_idContainer056" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/KIN00933.png" alt="" />
				</div>
				<div id="_idContainer057" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-18</span> Central retinal artery occlusion (CRAO). <span class="figure-caption-bold">A,</span> Fundus photograph shows superficial macular opacification and a cherry-red spot in the foveola. <span class="figure-caption-bold">B,</span> Angiography image reveals preservation of a sector of superonasal macula related to cilioretinal vessels, perfused in this image. The patient had hand motions visual acuity. <span class="figure-source-note">(Courtesy of Hermann D. Schubert, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer059" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/AAX-9937.png" alt="" />
			</div>
		</div>
		<div id="_idContainer060" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 6-19</span> SD-OCT scan of a case of CRAO similar to the one shown in Figure 6-18 with cilioretinal artery sparing shows hyperreflectivity in the area of clinical opacification of the inner two-thirds of the retina in the affected areas (<span class="figure-caption-italic">X</span>). All retinal layers are identifiable in the area of retina perfused by the cilioretinal artery, adjacent to the optic nerve head. The retina in the fovea is spared from opacification, resulting in the appearance of a cherry-red spot on examination. Subfoveal fluid <span class="figure-caption-italic">(asterisk)</span> is variably present in these cases. <span class="figure-source-note">(Courtesy of Colin A. McCannel, MD.) </span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer063">
				<div id="_idContainer061" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/KIN00204.png" alt="" />
				</div>
				<div id="_idContainer062" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-20</span> Central retinal and parent short ciliary artery occlusion. <span class="figure-caption-bold">A,</span> Fundus photograph of acute central retinal and short ciliary artery obstruction. Severe retinal opacification is present. The patient’s visual acuity was no light perception. <span class="figure-caption-bold">B,</span> Fluorescein angiography image taken 3&#160;minutes after injection reveals hypofluorescence of the retinal vessels, the nasal choroid, and the optic nerve head, corresponding to an occlusion of the central retinal artery and nasal parent ciliary artery. The latter results in ischemia in the distribution of the short posterior ciliary arteries with a vertical watershed of choroidal perfusion. <span class="figure-source-note">(Courtesy of Hermann D. Schubert, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer066">
				<div id="_idContainer064" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/AAX-8442.png" alt="" />
				</div>
				<div id="_idContainer065" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 6-21</span> Fundus photographic montage of the left eye of a 44-year-old woman following an ipsilateral injection of synthetic calcium hydroxylapatite gel into her left lateral lower eyelid for cosmetic purposes. Sudden loss of vision ensued to the level of no light perception. An ophthalmic artery occlusion occurred from presumed retrograde flow of the injectable cosmetic filler into the ophthalmic artery by way of anastomotic arteries in the orbit bridging the internal and external carotid circulations. The white filler material is visible in the retinal circulation and choroidal blood vessels. <span class="figure-source-note">(Courtesy of Kathryn Sun, MD, PhD, Thomas F. Essman, MD, and Brenda Schoenauer, CDOS.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer067" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 6-22</span><span class="figure-caption-bold"> </span>Fundus photograph of a retinal arterial macroaneurysm with some exudate in the superior macula, resulting from leakage of the lesion, and mild hemorrhage. <span class="figure-source-note">(Courtesy of Colin A. McCannel, MD.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer068" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C06_p121-148_pass_2p-web-resources/image/KIN00935.jpg" alt="" />
			</div>
		</div>
	</body>
</html>
